Steering Committee

The NARCRMS Steering Committee is comprised of the Project Director/Co-Directors; selected active members of the CMSC; the CMSC Chief Executive Officer (CEO); the chair of the Industry Advisory Board; and representatives of collaborating MS Registries, clinical databases, sites, and the National MS Society and shall not exceed 20 members. The committee is chaired by the Project Director/Co-Directors.

Please click on each name to view member’s brief biography.

Peter Aupperle

Acorda Therapeutics

Peter Aupperle, MD, MPH has devoted his entire career to Neuroscience, both in Industry and Academia. He started his Industry career as a Medical Director on the Pfizer Alzheimer’s disease team. He then spent several years as a Senior Medical Director, CDMA, at Novartis working on diverse CNS programs as well as development programs in spinal cord injury, an Alzheimer’s vaccine, and a novel anti-depressant. During his tenure at Novartis he also launched a new antipsychotic medication and was the medical lead on various marketed products. Peter is currently an Executive Medical Director at Acorda Therapeutics and is Head of the Ampyra and neuropathic pain teams.

Prior to entering pharmaceuticals, Peter spent 10 years at Robert Wood Johnson Medical School in New Jersey, where he still holds the title of Clinical Professor. He was the Director of New Jersey’s designated Alzheimer’s Institute, where he conducted dozens of clinical trials and he also directed the Division of Geriatric Psychiatry. Peter completed his undergraduate degree at Princeton University and received both an M.D. and MPH from Columbia University. His residency and fellowship were at Mt. Sinai in New York City.

×
Peter Aupperle

Peter Aupperle

Acorda Therapeutics

Stanley Cohan

Providence Stroke Center

Stanley Cohan was born in New York City and received his under-graduate education at Kenyon College, where he received his BA degree. He subsequently attended the State University of New York, Downstate Medical Center, where he was the recipient of the National Research Careers Fellowship, obtaining his PhD in 1967 and his MD in 1968. After serving 2 years in the US Navy, where he was head of the division of neuroscience research, he joined the faculty at Georgetown University, where he remained until 2000, retiring as tenured professor of neurology, adjunct professor of pharmacology, and chairman of neurology. He subsequently moved to Portland Oregon and is the founding director of the Providence Multiple Sclerosis Center and founder of the NW Multiple Sclerosis Registry. His primary interests are in new drug development for MS and MS epidemiology.

×
Stanley Cohan

Stanley Cohan

Providence Stroke Center

Anne Cross

Washington University in St. Louis

Anne Cross, M.D., earned her medical degree from the University of Alabama, completed neurology residency at George Washington University and then spent six years of fellowship training in neuroimmunology at the National Institutes of Health, molecular biology at Saint Jude Children's Research Hospital, and neuropathology at Albert Einstein College of Medicine. While at Einstein, she was awarded the Harry Weaver Neuroscience Scholar Award of the National Multiple Sclerosis Society. Dr. Cross joined the faculty at Washington University School of Medicine in St. Louis in 1991, where she now holds the Manny and Rosalyn Rosenthal–Dr. John L. Trotter endowed chair in neuroimmunology and is co-director of the John L. Trotter Multiple Sclerosis Clinic at Barnes-Jewish Hospital.

Dr. Cross has devoted her career of over 30 years to the study of MS. Her work has focused on understanding the mechanisms involved in pathogenesis of inflammation and demyelination in the central nervous system, and more recently, in using new methods to image the CNS of MS patients. Dr. Cross demonstrated that B cells in the immune system play an important role in an animal model of MS, which supported eventual clinical trials by her group and several others showing that B cell depletion was beneficial in relapsing MS patients. Dr. Cross’ current work includes the development of novel imaging techniques to non-invasively identify demyelination versus axonal loss versus inflammation in the CNS of living animals and patients.

×
Anne Cross

Anne Cross

Washington University in St. Louis

Gary Cutter

University of Alabama, Birmingham

Gary Cutter,  MS Ph.D.
Dr. Cutter is a Professor of Biostatistics and Head of the Section on Research Methods and Clinical Trials (RMCT Section) at the UAB School of Public Health.  Dr. Cutter has a major interest in design, analysis and interpretation of clinical trials, epidemiologic studies and evaluation research.  He directs three multinational coordinating centers; the CombiRx - combination therapy trial in MS; MGTX - a surgical trial in Myasthenia Gravis, both funded by NINDS and the NARCOMS registry of over 36,000 MS patients funded by the Consortium of MS Centers and private sources. He directs two Coordinating Centers in premature infants, both multi-center trials funded by the Lung Division of NHLBI.  He is Deputy Director of the Operations Center for the Neurofibromatosis Consortium and the Director, Biostatistics/Bioinformatics Resource (BBR) Core for the Obrien Center for Acute Kidney Injury Research, UAB-USC (NIDDK); Director, Center For Aids Research, Biostatistics Core, UAB (NIAID) and other multicenter trials. He is a member of the Executive Committee of the UAB CCTS, one of the NIH CTSA projects.  He is a member of numerous data and safety monitoring committees for the NIH, Pharmaceutical Companies and foundations.  He has been active in evaluation and outcome measures especially the Multiple Sclerosis Functional Composite.

×
Gary Cutter

Gary Cutter

University of Alabama, Birmingham

Andrew Goodman

University of Rochester Medical Center

Andrew D. Goodman, MD, FAAN, FANA, is Professor of Neurology, Chief of the Neuroimmunology Division, and Director of the Multiple Sclerosis Center at the University of Rochester.

Dr. Goodman’s interests include clinical and experimental therapeutics research. He has been the lead investigator (or a member of the steering committee) for various national and international clinical trials of new therapies for multiple sclerosis including natalizumab and dalfampridine. He is currently a member of the protocol committee and site-PI for the “SPRINT MS” study of ibudilast in secondary progressive MS sponsored by NeuroNext (NIH) and NMSS. Dr. Goodman is a co-PI of a project funded by the New York State Stem Cell program (NYSTEM) that plans to perform a phase 1, first in man study testing the safety of transplanting oligodendrocyte precursor cells into the cerebral white matter of patients with progressive multiple sclerosis.

He is a past chair of the MS section of the AAN. He has also served on the International Advisory Committee on Clinical Trials in MS, the ACTRIMS Board of Directors, and the Executive Committee of the NMSS Clinical Advisory Committee.

Dr. Goodman is a graduate of Rutgers College and the Rutgers New Jersey Medical School; he did residency training in internal medicine and neurology at Mt. Sinai Medical Center in New York City. He completed a research fellowship in the Neuroimmunology Branch at the National Institutes of Health, Bethesda, Maryland.

×
Andrew Goodman

Andrew Goodman

University of Rochester Medical Center

Corey Ford

University of New Mexico

Corey C. Ford, is a board certified neurologist in academic practice at the University of New Mexico Health Sciences Center in Albuquerque. He has a PhD degree in Biophysics from the University of Texas Health Sciences Center at Dallas and attended medical school at the University of Virginia. His neurology training was completed at the University of Rochester, where he stayed an additional two years as a fellow in the multiple sclerosis division. In 1988 he joined the Neurology faculty at the University of New Mexico where he established the Multiple Sclerosis Specialty Clinic. The MS program at UNM is very active in clinical research studies of new treatments and applications of neuroimaging for MS. UNM's MS Clinic is a long‑standing member of the CMSC and a Partner in Care with the NMSS. Dr. Ford is currently Sr. Associate Dean for Research in the School of Medicine. He is director of the Regulatory Knowledge and Support component of the UNM Clinical and Translational Science Center and directs the Brain and Behavioral Health Institute and other Signature Programs at UNMHSC.

×
Corey Ford

Corey Ford

University of New Mexico

June Halper

Consortium of MS Centers

June Halper is a certified adult nurse practitioner who has specialized in multiple sclerosis since 1978

She has published and lectured extensively on multiple sclerosis and its ramifications. Her numerous publications include Comprehensive Nursing Care in Multiple Sclerosis and Advanced Concepts in Nursing Care in Multiple Sclerosis, co-editor of Staying Well with Multiple Sclerosis: A Self-Care Guide, and co-editor of Nursing Practice in Multiple Sclerosis: A Core Curriculum.

She initiated the first certification examination for MS nurses in 2002 and for MS specialists in 2004.

As early as 1995, Ms. Halper was involved in the development of clinical practice guidelines in multiple sclerosis which were multi-organization collaborative projects. The CMSC has adopted a best practices model and Ms. Halper was involved in publication of models of comprehensive care, complex symptomatic management, and cognition to name a few publications. (please visit www.mscare.org for a full listing)

In 1995 the CMSC/NARCOMS patient registry was established under Ms. Halper’s leadership and support. Since that time the registry has been a source of information about outcome measures and a resource for quality improvement projects. A clinical longitudinal database, NARCRMS, will be launched in 2015.

She oversaw the development and implementation of certification examinations in MS Nursing, MS Certified Specialists, and most recently, certification in Rare Neuroimmunological Diseases (CRND).

Ms. Halper continues to be involved in clinical care as a nurse practitioner at the MS Center of the New Jersey Medical School, Rutgers University, Newark, New Jersey and at primary care clinic.

×
June Halper

June Halper

Consortium of MS Centers

Colleen Harris

Calgary - Alberta Health Services

Colleen Harris is the Nurse Co-ordinator/Nurse Practitioner of the University of Calgary MS Clinic, where she has been involved in multi-disciplinary care for much of her nursing career. She completed a diploma-nursing program at Foothills Hospital and later obtained both a Bachelor’s and Master’s Degree in nursing, as well as a post Masters Nurse Practitioner Certificate through the University of Calgary. She holds an Adjunct Assistant Professor appointment with the faculty of Nursing at the University of Calgary. She sat on the Alberta MS Special Therapies Review Panel for 13 years and gave input on the approval and funding of new MS Therapies. Her interests specific to MS include intrathecal baclofen therapy, pain management, health outcomes research, and nursing education. Colleen, along with several of her MS nursing colleagues from North America, Europe and Australia, was involved in the creation of the International Organization of MS nurses (IOMSN) and is one of the past presidents of this organization. She has been active in committee and project work with the Consortium of MS Centers (CMSC) for 16 years and is a past president of this organization.

×
Colleen Harris

Colleen Harris

Calgary - Alberta Health Services

Stephen Hauser

University of California, San Francisco

Stephen L. Hauser, M.D. is the Robert A. Fishman Distinguished Professor and Chair of the Department of Neurology at the University of California, San Francisco. A neuroimmunologist, Dr. Hauser’s research has advanced our understanding of the genetic basis, immune mechanisms, and treatment of multiple sclerosis.

Dr. Hauser is a fellow of the American Academy of Arts and Sciences and the American Academy of Physicians, a member of the Institute of Medicine of the National Academy of Sciences (former Chair of Committee on Gulf War and Health Outcomes and current Chair of Committee on Long Term Effects of Blast Exposure), an editor of the textbook Harrison’s Principles of Internal Medicine. He has served as editor-in-chief of Annals of Neurology and is a former President of the American Neurological Association and President of the Medical Staff at UCSF. He also serves on several scientific advisory boards for nonprofit organizations.

Dr. Hauser has received numerous awards and honors for his work, including the Jacob Javits Neuroscience Investigator Award, the John Dystel Prize and the Charcot Award for Multiple Sclerosis Research. In April 2010 Dr. Hauser was appointed by President Obama to the Presidential Commission for the Study of Bioethical Issues charged with advising the President on issues that may emerge from advances in biomedicine and related areas of science and technology.

He is a graduate of MIT (Phi Beta Kappa) and Harvard Medical School (Magna Cum Laude). He trained in internal medicine at the New York Hospital–Cornell Medical Center, in neurology at the Massachusetts General Hospital (MGH), and in immunology at Harvard Medical School and the Institute Pasteur in Paris, France, and was a faculty member at Harvard Medical School before moving to UCSF.

×
Stephen Hauser

Stephen Hauser

University of California, San Francisco

Stefan Lanker

Biogen Idec Inc.

Stefan Lanker, Ph.D; Scientific & Medical Director at Biogen Idec

As the Biogen U.S. Scientific Director, Stefan oversees all U.S. Collaborative Research between Biogen and Academic Research Centers. Stefan is a core voting member on Biogen’s Clinical Trial Review committees, and leads the U.S. Medical Scientific Collaborations Team. Stefan is the head of the U.S. MS Registry initiative and U.S. Medical Director for the anti-LINGO and Alzheimer Disease programs. Before joining Biogen Idec, Stefan was a clinical instructor at Oregon Health & Science University where he received the Oregon Medical Research Foundation Award. He also was a Member of the Oregon Cancer Institute and Assistant Professor at the Department of Molecular Biology and Medical Genetics at the Oregon Health & Science University. Stefan was a Postdoctoral Fellow at The Scripps Research Institute after obtaining his Ph.D. at the University of Bern, Switzerland.

 

×
Stefan Lanker

Stefan Lanker

Biogen Idec Inc.

David E. Jones

University of Virginia

David E. Jones, MD is an fellowship trained MS-neurologist who is currently at the University of Virginia. He completed medical school at the Wake Forest University School of Medicine, and then he did his neurology residency at the University of Massachusetts. He stayed at UMass for his MS / neuro-immunology fellow-ship, which was funded by the National MS Society. After that, he worked at Lehigh Valley Health Network, for 4 years, where he was director of the MS Center of the Lehigh Valley, which was a NMSS-affiliated Center for Comprehensive Care.

In 2012, Dr. Jones joined the faculty at the University of Virginia Health System as an Assistant Professor of Neurology. In 2012-2013, he was vice-chair of the MS Section of the American Academy of Neurology, and in 2014, he was elected chair of the MS Section. He is director of Clinical Operations for the James Q. Miller MS Clinic at UVa. He is on the Medical Advisory Board of the MS Foundation, is a program consultant for Can Do MS, and is a member of the MS Coalition Emerging Therapies Collaborative.

×
David E. Jones

David E. Jones

University of Virginia

Nicholas LaRocca

National MS Society

Dr. Nicholas LaRocca is a clinical psychologist who has worked in the field of MS for over 30 years. He was an associate professor at Albert Einstein College of Medicine and New York Medical College before joining the Society in 1997. He currently serves as Vice President of Health Care Delivery and Policy Research in the Advocacy, Services, and Research Department of the Society. In this role he has responsibility for Society funding of research to address the symptoms of MS, rehabilitation, epidemiology, psychosocial aspects of MS as well as health policy studies. He has a longstanding interest in cognition and rehabilitation and co-authored a book on cognitive changes in MS that was published in 2006. During the last several years he has worked with the Agency for Toxic Substances and Disease Registry and the Centers for Disease Control and Prevention on the establishment of a national registry for MS, Parkinson’s Disease, and other neurological conditions. In 2011 he was appointed to the National Advisory Board on Medical Rehabilitation Research at the National Institutes of Health and was chairperson of that advisory board in 2013-2014. Dr. LaRocca is also co-director of the Multiple Sclerosis Outcome Assessments Consortium, a Society initiative to develop and qualify a new measure of disability for use in clinical trials of MS therapies.

×
Nicholas LaRocca

Nicholas LaRocca

National MS Society

David Li

The University of British Columbia

David K.B. Li, is Professor of Radiology and Associate Member in Neurology at the University of British Columbia (UBC) and Director of the UBC MS/MRI Research Group. He was formerly Head of Radiology at the UBC Hospital and Interim Head, Department of Radiology, University of British Columbia. After obtaining his medical degree and radiology residency at UBC, which included additional training in nuclear medicine at Harvard Medical School and body CT at University of California (San Francisco), he did postgraduate studies in MRI at the Royal Postgraduate Medical School (London). His primary research interest is the application of MR techniques in the study of patients with multiple sclerosis.

×
David Li

David Li

The University of British Columbia

Robert P Lisak

Wayne State University School of Medicine

Robert P Lisak, MD, FRCP (UK), FAAN, FANA, is Parker Webber Professor in Neurology, Professor of Neurology and Professor of Immunology and Microbiology at Wayne State University School of Medicine. Dr Lisak received his BA from University College of Arts and Sciences of New York University and his MD from the College of Physicians and Surgeons of Columbia University. He trained in internal medicine at Montefiore Hospital and Medical Center and Bronx Municipal Hospital (Albert Einstein College of Medicine of Yeshiva University) and in neurology and allergy and immunology at the University of Pennsylvania. Dr Lisak served as a research fellow in Biochemistry/Neurochemistry at the National Institute of Mental Health in Bethesda. He was a member of the Department of Neurology as well as the Immunology Graduate Program and an associate member of the Institute of Neuroscience at the University of Pennsylvania prior to joining the faculty at Wayne State University in 1987. He served as chair of Neurology at Wayne State University from 1987-2012. Dr Lisak has served on the editorial boards of several journals and as editor in chief of the Journal of the Neurological Sciences, the journal of the World Federation of Neurology, from 1997-2012. He has served in leadership positions for several profession/scholarly organizations including the American Academy of Neurology, the American Neurological Association, the International Society for Neuroimmunology and the Consortium of Multiple Sclerosis Centers (CMSC) where he is currently President of the Consortium and Chair of the Board of the Foundation of the CMSC (FCMSC). He has served on multiple committees for the CMSC, the National MS Society, NINDS/NIAID as well other organizations. Dr Lisak has been involved in basic, clinical and translational research in neuroimmunologic diseases for 50 years including multiple sclerosis and related disorders, myasthenia gravis and autoimmune/immune mediated neuropathies and myopathies.

×
Robert P Lisak

Robert P Lisak

Wayne State University School of Medicine

Fred Lublin

The Mount Sinai Hospital

Fred D. Lublin, M.D. is the Saunders Family Professor of Neurology at The Icahn School of Medicine at Mount Sinai and Director of the Corinne Goldsmith Dickinson Center for Multiple Sclerosis at that institution.

Dr. Lublin received his medical degree in 1972 from Jefferson Medical College, Philadelphia, PA. He completed his internship in Internal Medicine from the Bronx Municipal Hospital, Albert Einstein Medical Center, and his residency at the New York Hospital, Cornell Medical Center.

As a neuroimmunologist, Dr. Lublin has a special interest in immune functions and abnormalities affecting the nervous system. He has been involved in both basic science and clinical research. He and his colleagues were among the first in the country involved with studies of Interferon beta-1b, which was approved by the Food & Drug Administration in 1993 to treat the relapsing-remitting form of Multiple Sclerosis. He is currently involved with several new clinical research protocols on promising agents for treating various aspects of MS. He was chairman of the National MS Society (USA) advisory committee on clinical trials of new drugs in Multiple Sclerosis and the National Multiple Sclerosis Society’s Research Programs Advisory Committee. He is a member of the National MS Society National Board of Directors. He is immediate past Chair of the New York City/Southern New York Chapter of NMSS Clinical Advisory Committee. He is a member of the International Medical & Scientific Board of the Multiple Sclerosis International Federation. Dr. Lublin and his colleagues at the National MS Society have re-defined the clinical course definitions of MS, updated in 2014. He has chaired a task force on the ethics of placebo-controlled trials in MS. Dr. Lublin is a member of the international panel that periodically redefines the diagnostic criteria for MS. Dr. Lublin is co-chair of the National Institute of Neurological Diseases and Stroke MS Common Data Element committee and a member of their steering committee. He is a member of the WHO Advisory Group for the Revision of ICD-10 Diseases of the Nervous System working group on demyelinating diseases of the central nervous system. He is a Co-Chief Editor of the journal Multiple Sclerosis and Related Disorders.

Dr. Lublin has published numerous scientific articles and belongs to many professional societies and advisory boards. Dr. Lublin has served as a consultant to the National Institutes of Health and to many pharmaceutical/biotech companies in all phases of new drug development and in preparation for presentation to the FDA and their advisory panels. He is the Principal Investigator of the NIH-sponsored multicenter Combination Therapy study in Multiple Sclerosis.

×
Fred Lublin

Fred Lublin

The Mount Sinai Hospital

Aaron Miller

Icahn School of Medicine at Mount Sinai

Dr. Miller graduated from Brandeis University in 1964 and received his MD degree from New York University School of Medicine in 1968. Following his residency in neurology at the Albert Einstein College of Medicine, he received additional postdoctoral training in neurovirology and immunology at the Johns Hopkins University School of Hygiene and Public Health and at Einstein. During this time, he was the recipient of a fellowship from the National MS Society. In March, 2004, Dr. Miller assumed the position of Medical Director of the Corinne Goldsmith Dickinson Center for Multiple Sclerosis at the Icahn School of Medicine at Mount Sinai. For 23 years prior to that, he headed the Division of Neurology at Maimonides Medical Center in Brooklyn, NY where he continues to serve as co-director of the MS Care Center. Dr. Miller is also a Professor of Neurology at the Icahn School of Medicine at Mount Sinai in New York.

Dr. Miller became the chief medical officer of the National MS Society in October 2001 and continues to serve as its senior medical advisor. He also served as chairman of the National Clinical Advisory Board of the NMSS from 2001 through 2009. He served as chairman of the Clinical Advisory Committee of the New York Chapter of the NMSS from 1991--2004. He formerly served as the chairman of the Professional Education Committee of the NMSS and is a past president of the Consortium of MS Centers. He was the first chairman of the Multiple Sclerosis section of the American Academy of Neurology. He has participated in numerous clinical trials of new treatments for MS. He has authored two books, Multiple Sclerosis in Clinical Practice, with colleagues Fred Lublin and Patricia Coyle and Neuroimmunology as part of the What Do I Do Now? Series with Tracy DeAngelis. He has also published many articles and chapters on MS and other neurological subjects. He developed and for many years participated in a popular seminar at the annual meeting of the American Academy of Neurology entitled MS: Patient Management, for four years directed a course entitled Update on Multiple Sclerosis, and then for four years directed a course on “Hot Topics in Multiple Sclerosis.” In 2010, he introduced a new course for the AAN annual meeting entitled “Multiple Sclerosis Essentials.”

Dr. Miller is also very active with the American Academy of Neurology, for which he served as a member of the Board of Directors from 2009—2013 and currently serves at the Secretary of that Board. He recently completed 10 years as Editor of Continuum, the bimonthly continuing education publication of the AAN, and currently serves as Editor of Continuum Audio. He was a member of the Education Committee from 1989—2009 and the Meeting Management Committee from 1997--2009. From 1997—2003, he served as Co-chairman of the Education Committee and Chairman of the Annual Meeting Subcommittee. Prior to assuming that position, he served as chairman of the Program Accreditation and Development Subcommittee.

Dr. Miller has been cited by New York Magazine in its list of Top Doctors from 2008—2012 and has been included in Castle Connolly’s book of America’s Top Doctors in 2009--2013.

×
Aaron Miller

Aaron Miller

Icahn School of Medicine at Mount Sinai

Michael Racke

The Ohio State University

Michael K. Racke received his M.D. from the University of Medicine and Dentistry of New Jersey-New Jersey Medical School. He completed his neurology training at Emory University in Atlanta and a neuroimmunology fellowship at the National Institutes of Health. His first faculty position was at Washington University in St. Louis, where he was the recipient of a Harry Weaver Neuroscience Junior Faculty Award from the National Multiple Sclerosis Society and the Young Investigator in Multiple Sclerosis of the American Academy of Neurology Education and Research Foundation. He then moved to the University of Texas Southwestern Medical Center where he was Vice Chairman for Neurology Research and also professor in the Center for Immunology. He was chairman of neurology at The Ohio State University School of Medicine from 2006-2014. His research focuses on understanding how inflammation gets established in the central nervous system and developing novel therapeutics by studying the animal model experimental autoimmune encephalomyelitis. His research also centers on the pathogenesis of multiple sclerosis. Dr. Racke has served on scientific advisory committees for the National Multiple Sclerosis Society, National Institutes of Health, and the Hertie Foundation as well as on several editorial boards. Contact information: 395 West 12th Avenue, The Ohio State University Wexner Medical Center, Columbus, OH 43210; Phone 614-293-6354; email: Michael.Racke@osumc.edu

 

×
Michael Racke

Michael Racke

The Ohio State University

Kottil Rammohan

University of Miami

Kottil W. Rammohan, MD, is a Professor of Neurology and the Director of the Multiple Sclerosis Center at the University of Miami, Miami, FL. He is board certified by the American Board of Internal Medicine, and the American Board of Psychiatry and Neurology with special competence in Neurology.

A graduate of Madras Medical College in Chennai, India, Dr. Rammohan completed an internship at the Cook County Hospital in Chicago, and trained as a resident in Internal Medicine and Neurology at The Ohio State University. He was a Fellow and Senior Clinical Associate at the National Institutes of Health where he trained in the fields of Neurovirology and Neuroimmunology under the tutelage of Dr. Henry McFarland, and the late Dr. Dale McFarlin.

A participant in a number of investigator and industry initiated clinical trials, Dr. Rammohan’s main research interest is in understanding the pathogenesis and treatment of multiple sclerosis (MS). In particular, he has been involved with understanding mechanisms of fatigue, and designing treatments for this disabling symptom.  He had special interests in understanding MS by magnetic resonance imaging, specifically, imaging MS brain abnormalities at Ultra high field strength (8 tesla). His contributions include developing novel and simple techniques for examination of abnormalities in the cerebrospinal fluid in MS. At a basic level, his interests include exploring autoimmunity to ion channels in MS and exploring mechanisms of action of the presently used disease modifying therapies in multiple sclerosis.

Integrally involved in the study of MS, Dr. Rammohan has served the National Multiple Sclerosis Society as a member of both the Medical Advisory Board and the Clinical Care Committee. He chaired the Clinical Advisory Committee at the National level. He is a member of a number of data safety monitoring and Steering committees for national and international Phase 2 and 3 clinical trials.

Dr. Rammohan was recognized for his support of MS with the following national honors: The Hope Award, The Spirit Award, Outstanding Physician Recognition Award, MS Society Volunteer Hall of Fame, and Best Doctors in America.

×
Kottil Rammohan

Kottil Rammohan

University of Miami

Anthony Traboulsee

The University of British Columbia

Anthony Traboulsee is an Associate Professor and Research Chair of the MS Society of Canada at the University of British Columbia in Vancouver, Canada. He is the Medical Director of the MS Clinic, Assistant Director of the MS/MRI Research Group, and Director of the MS Clinical Trials Research Group at the University of British Columbia Hospital. He received his B.Sc. from McGill University in Montreal, Canada and his M.D. from Dalhousie University in Halifax, Nova Scotia. He completed a residency in Neurology and fellowship in Multiple Sclerosis at the University of British Columbia Hospital in Vancouver and University College London (Queen Square). His research focus is on the development of practice guidelines for routine use of MRI in the management of MS, establishing advanced MRI imaging outcomes in Multiple Sclerosis, and the treatment of Neuromyelitis Optica.

×
Anthony Traboulsee

Anthony Traboulsee

The University of British Columbia

Howard Weiner

Partners Healthcare

Howard L. Weiner is the Robert L. Kroc Professor of Neurology at the Harvard Medical School, Director and Founder of the Partners Multiple Sclerosis Center and Co-Director of the Center for Neurologic Diseases at the Brigham & Women's Hospital. Dr. Weiner established the Partners Multiple Sclerosis Center at Brigham & Women's Hospital in 2000 which combines clinical evaluation, MRI imaging and immune monitoring and is the first integrated MS center that brings these disciplines to the individual care of the MS patient. Dr. Weiner has pioneered the use of immunotherapy and the drug cyclophosphamide for the treatment of multiple sclerosis and has investigated immune abnormalities in the disease including the role of the innate immune system and regulatory T cells. He has also pioneered the use of the mucosal immune system for the treatment of autoimmune and other diseases. Based on his work vaccines are being tested in multiple sclerosis, diabetes, and most recently in Alzheimer's disease. Dr. Weiner is the author of "Curing MS: How Science is Solving the Mystery of Multiple Sclerosis" that chronicles the history of MS, his 30+ years in the research and clinical treatment of MS, and details his "21 point hypothesis" on the etiology and treatment of multiple sclerosis. In 2004 Harvard Medical School honored Dr. Weiner with the establishment of the Howard L. Weiner Professor of Neurology Endowed Chair.

Dr. Weiner is the 2007 recipient of the John Dystel Prize for Multiple Sclerosis Research awarded by the American Academy of Neurology and in 2008 received the Betty and David Koetser Memorial Prize as awarded by the Betty and David Koetser Foundation for Brain Research. In 2009, Dr. Weiner was presented the Award for Outstanding Research Achievement, Nature Biotechnology SciCafé, Nature Publications. In 2012 Dr. Weiner received the NIH Director’s Transformative Research Award.

×
Howard Weiner

Howard Weiner

Partners Healthcare